[Diagnostics and management of herpes zoster ophthalmicus]

Ophthalmologe. 2017 Oct;114(10):959-972. doi: 10.1007/s00347-017-0562-3.
[Article in German]

Abstract

Herpes zoster (HZ, shingles) represents the secondary manifestation of an infection with varicellazoster virus (VZV). A reactivation of dormant VZV in the ophthalmic branch of the fifth cranial nerve leads to ophthalmic HZ (HZO). The predominantly older and immune compromised patients often present with eye involvement (approximately 50%) as well as characteristic skin changes. Clinical manifestations include the cornea and conjunctiva but anterior uveitis and (rarely) acute retinal necrosis may also occur. Associated sensory symptoms that range from paresthesia to severe pain may severely affect the quality of life. Particularly in immunocompromised and/or elderly patients, HZO is associated with complicated courses. Systemic antiviral treatment and an adequate pain medication are the mainstay of the recommended management. The present article provides an overview of the contents of the current consensus-based European guidelines on the management of HZ with a specific focus on HZO.

Keywords: Acute retinal necrosis syndrome; Anterior uveitis; Complications; Guidelines; Shingles.

MeSH terms

  • Adrenal Cortex Hormones / therapeutic use
  • Analgesics / therapeutic use
  • Antiviral Agents / therapeutic use
  • Combined Modality Therapy
  • Diagnosis, Differential
  • Fluorescein Angiography
  • Guideline Adherence
  • Herpes Zoster Ophthalmicus / diagnosis*
  • Herpes Zoster Ophthalmicus / drug therapy
  • Humans
  • Keratitis, Dendritic / diagnosis
  • Keratitis, Dendritic / drug therapy
  • Nerve Growth Factor / therapeutic use
  • Retinal Necrosis Syndrome, Acute / diagnosis
  • Retinal Necrosis Syndrome, Acute / drug therapy
  • Uveitis, Anterior / diagnosis
  • Uveitis, Anterior / drug therapy
  • Visual Analog Scale

Substances

  • Adrenal Cortex Hormones
  • Analgesics
  • Antiviral Agents
  • Nerve Growth Factor